Brokers Offer Predictions for ETRA Q3 Earnings

Key Points

• HC Wainwright forecasts Electra Therapeutics will report a Q3 2026 loss of $0.56 per share and maintains a Buy rating with a $30 price target. It also projects a $3.17-per-share loss for full-year 2026.
• Analyst sentiment is broadly positive: ETRA has an average Buy rating and a $33.50 consensus price target, with other firms setting targets as high as $36.
• Electra shares opened at $8.52, near their 52-week low of $8.26, while directors Orbimed Advisors and Carl Gordon each purchased 1.33 million shares at $15 per share in September.

Electra Therapeutics, Inc. (NASDAQ:ETRA - Free Report) - Stock analysts at HC Wainwright issued their Q3 2026 earnings estimates for shares of Electra Therapeutics in a research report issued to clients and investors on Monday, October 26th. HC Wainwright analyst R. Selvaraju forecasts that the company will earn ($0.56) per share for the quarter. HC Wainwright has a "Buy" rating and a $30.00 price target on the stock. The consensus estimate for Electra Therapeutics' current full-year earnings is ($3.55) per share. HC Wainwright also issued estimates for Electra Therapeutics' Q4 2026 earnings at ($0.53) EPS, FY2026 earnings at ($3.17) EPS, Q1 2027 earnings at ($0.55) EPS, Q2 2027 earnings at ($0.60) EPS, Q3 2027 earnings at ($0.64) EPS, Q4 2027 earnings at ($0.70) EPS and FY2027 earnings at ($2.48) EPS.

ETRA has been the topic of a number of other research reports. Evercore began coverage on Electra Therapeutics in a research report on Tuesday, October 13th. They set an "outperform" rating and a $36.00 price objective on the stock. Jefferies Financial Group started coverage on Electra Therapeutics in a report on Tuesday, October 13th. They issued a "buy" rating and a $32.00 target price for the company. TD Cowen began coverage on shares of Electra Therapeutics in a research report on Tuesday, October 13th. They set a "buy" rating for the company. Wall Street Zen raised shares of Electra Therapeutics to a "hold" rating in a research note on Saturday, September 26th. Finally, Cantor Fitzgerald initiated coverage on shares of Electra Therapeutics in a report on Tuesday, October 13th. They issued an "overweight" rating on the stock. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, Electra Therapeutics has an average rating of "Buy" and an average price target of $33.50.

Electra Therapeutics Stock Up 1.8%

ETRA opened at $8.52 on Wednesday. Electra Therapeutics has a 1-year low of $8.26 and a 1-year high of $15.50.

Insider Buying and Selling at Electra Therapeutics

In other Electra Therapeutics news, Director Orbimed Advisors Llc purchased 1,333,333 shares of the stock in a transaction dated Monday, September 21st. The stock was acquired at an average cost of $15.00 per share, for a total transaction of $19,999,995.00. Following the acquisition, the director owned 5,126,891 shares in the company, valued at $76,903,365. This trade represents a 35.15% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Carl Gordon acquired 1,333,333 shares of the business's stock in a transaction that occurred on Monday, September 21st. The shares were acquired at an average cost of $15.00 per share, with a total value of $19,999,995.00. Following the completion of the transaction, the director directly owned 5,126,891 shares in the company, valued at approximately $76,903,365. The trade was a 35.15% increase in their position. The SEC filing for this purchase provides additional information.

Electra Therapeutics Company Profile

Electra Therapeutics, Inc NASDAQ: ETRA is a clinical-stage biopharmaceutical company focused on developing therapies that modulate the immune system. The company's research is directed toward selectively influencing immune-cell activity to address serious diseases, including cancer and autoimmune conditions.

Electra Therapeutics is advancing a pipeline of investigational medicines based on its immune-cell modulation approach. Its programs are intended to improve the body's ability to recognize, control, or eliminate disease-associated cells while limiting effects on healthy tissue.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.